Valeo to sell PharmaMar's Yondelis in Canada

21 January 2020

Spanish drugmaker PharmaMar (MSE: PHM) has announced a licensing deal with Quebec-based Valeo Pharma (CSE: VPH) for the Canadian commercialization of the marine-derived cancer drug Yondelis (trabectedin).

PharmaMar, which will retain the exclusive production rights and will sell the product to Valeo for its clinical and commercial use, will receive a non-disclosed upfront sum and will be eligible for additional remunerations, including regulatory milestone payments.

This new agreement follows PharmaMar's recovery of commercialization rights for Yondelis from Janssen, in more than 40 countries, where the product has already been approved. It was announced in August that the Johnson & Johnson (NYSE: JNJ) unit would be handing back the rights.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK